2012 | A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia | 허정원; 문영철 | Article |
2006 | A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma | 성주명 | Article |
2011 | Adverse prognostic impact of abnormal lesions detected by genome-wide single nucleotide polymorphism array-based karyotyping analysis in acute myeloid leukemia with normal karyotype | 허정원; 문영철 | Article |
2014 | Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: Web-based multicenter registry study | 문영철 | Article |
2009 | Clinical features and survival outcomes in patients with multiple myeloma: Analysis of web-based data from the korean myeloma registry | 문영철 | Article |
2014 | Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia | 성주명 | Article |
2013 | Different characteristics identified by single nucleotide polymorphism array analysis in leukemia suggest the need for different application strategies depending on disease category | 허정원 | Article |
2018 | Efficacy and safety of a new 10% intravenous immunoglobulin product in patients with primary immune thrombocytopenia (ITP) | 문영철 | Article |
2013 | Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia | 문영철 | Article |
2013 | Genome-wide genotype-based risk model for survival in acute myeloid leukaemia patients with normal karyotype | 문영철 | Article |
2011 | Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia | 허정원 | Article |
2013 | KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement | 문영철 | Article |
2018 | Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150) | 문영철 | Article |
2012 | Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia | 문영철 | Article |
2012 | Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: Results of a phase II trial | 성주명 | Article |
2017 | The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: A retrospective multicenter study (KMM160) | 문영철 | Article |